Asset Details
Do you wish to reserve the book?
Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease
Do you wish to request the book?
Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease
2012
Overview
Heart rate (HR) is an emerging risk factor in coronary artery disease (CAD). However, there is little contemporary data regarding HR and the use of HR-lowering medications, particularly beta-blockers, among patients with stable CAD in routine clinical practice. The goal of the present analysis was to describe HR in such patients, overall and in relation to beta-blocker use, and to describe the determinants of HR.
CLARIFY is an international, prospective, observational, longitudinal registry of outpatients with stable CAD, defined as prior myocardial infarction or revascularization procedure, evidence of coronary stenosis of >50%, or chest pain associated with proven myocardial ischemia. A total of 33,438 patients from 45 countries in Europe, the Americas, Africa, Middle East, and Asia/Pacific were enrolled between November 2009 and July 2010. Most of the 33,177 patients included in this analysis were men (77.5%). Mean (SD) age was 64.2 (10.5) years, HR by pulse was 68.3 (10.6) bpm, and by electrocardiogram was 67.2 (11.4) bpm. Overall, 44.0% had HR ≥ 70 bpm. Beta-blockers were used in 75.1% of patients and another 14.4% had intolerance or contraindications to beta-blocker therapy. Among 24,910 patients on beta-blockers, 41.1% had HR ≥ 70 bpm. HR ≥ 70 bpm was independently associated with higher prevalence and severity of angina, more frequent evidence of myocardial ischemia, and lack of use of HR-lowering agents.
Despite a high rate of use of beta-blockers, stable CAD patients often have resting HR ≥ 70 bpm, which was associated with an overall worse health status, more frequent angina and ischemia. Further HR lowering is possible in many patients with CAD. Whether it will improve symptoms and outcomes is being tested.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
Adrenergic beta-Antagonists - pharmacology
/ Adrenergic beta-Antagonists - therapeutic use
/ Adrenergic beta-Antagonists/pharmacology/therapeutic use
/ Aged
/ Angina
/ Cardiovascular & respiratory systems
/ Coronary Artery Disease - drug therapy
/ Coronary Artery Disease - physiopathology
/ Coronary Artery Disease/drug therapy/physiopathology
/ EKG
/ Factor Analysis, Statistical
/ Female
/ Humans
/ Ischemia
/ Male
/ Medicine
/ Pain
/ Patients
/ Sciences de la santé humaine
/ Stenosis
